Repurposing losartan for fibrostenosing Crohn’s disease: a compelling preclinical rationale - Takeaways - MDSpire

Repurposing losartan for fibrostenosing Crohn’s disease: a compelling preclinical rationale

  • By

  • Luca Massimino

  • Virginia Solitano

  • Federica Ungaro

  • September 23, 2025

  • 0 min

Share

  • 1

    Losartan, an angiotensin receptor blocker, shows promise in treating intestinal fibrosis associated with Crohn's disease.

  • 2

    The study demonstrated that losartan reduces inflammation and fibrosis in preclinical models of Crohn's disease.

  • 3

    Losartan effectively suppressed pro-fibrotic molecules and inhibited fibroblast-to-myofibroblast differentiation in vitro.

  • 4

    In SAMP mice, losartan treatment prevented fibrosis relapse after steroid-induced remission, highlighting its therapeutic potential.

  • 5

    The findings support the need for clinical trials on RAS-targeting therapies as adjuncts to current IBD treatments.

Original Source(s)

Repurposing losartan for fibrostenosing Crohn’s disease: a compelling preclinical rationale

  • by Luca Massimino, Virginia Solitano, Federica Ungaro

  • September 23, 2025

Related Content

Assessment of the quality and dependability of Crohn's disease-related information on Douyin and Xiaohongshu: Insights from user feedback in a cross-sectional analysis

Cause of chronic diarrhoea

Risk of intestinal involvement in mucocutaneous-onset Behçet’s disease: data from the AIDA network registry